mechanism-based covalent neuraminidase inhibitors broad-spectrum influenza antiviral activity 
influenza antiviral agents play important roles modulating disease severity controlling pandemics vaccines prepared development resistance agents like commonly used neuraminidase inhibitor oseltamivir may limit future utility report new class specific mechanism-based anti-influenza drugs function formation stabilized covalent intermediate influenza neuraminidase enzyme confirm mode action structural mechanistic studies compounds function cell-based assays animal models efficacies comparable neuraminidase inhibitor zanamivir broad-spectrum activity drug-resistant strains vitro similarity structure natural substrate mechanism-based design make attractive antiviral candidates 
